Search the Newsreel

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

ICU Medical VP Daniel Woolson sells $982,264 in stock

Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc. (NASDAQ:ICUI), sold 5,417 shares of the company's common stock for $982,264 on August 13, 2026, at $181.33 per share. This sale occurred as ICUI shares are near their 52-week high, following strong Q2 results where …

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

Celcuity Q2 Earnings Call Highlights

Key Points Interested in Celcuity, Inc.? Here are five stocks we like better. REVTORPYK launch remains on track: Celcuity expects commercial shipments of its FDA-approved gedatolisib therapy for certain advanced breast cancer patients to begin in late Q3 2026. The treatment has a $30,000 …

CURI | CuriosityStream Inc. Class A Financials - Revenue Breakdown

CELCUITY ($CELC) Releases Q2 2026 Earnings

ICU Medical (ICUI) officer Daniel Woolson sells 5,417 shares at $181.33

Daniel Woolson, VP and GM-Infusion Capital at ICU Medical Inc. (ICUI), sold 5,417 shares of common stock at $181.33 per share on August 13, 2026. After this transaction, Woolson directly holds 17,062 shares of ICU Medical common stock. The sale was not conducted under …

Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4

Citi has reiterated its Buy rating for Acumen Pharmaceuticals (ABOS.US) and maintained its target price at $4. This continued endorsement suggests the analyst firm sees ongoing potential or stability in the company's financial outlook and stock performance.

Form 8K Securitize Corp For: 13 August By Investing.com

This article reports on the filing of Form 8K by Securitize Corp on August 13. The brief piece from Investing.com serves as a notification regarding this SEC filing. No further details about the content of the Form 8K are provided.

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

DocuSign climbs as investors appear to lean on prior beat-and-raise results ahead of next earnings

DocuSign (DOCU) shares rose 9.6% due to continued investor optimism following its recent quarterly earnings beat and increased full-year outlook. The surge may also reflect positioning ahead of the company's next earnings report, with strong profitability and revenue guidance from the previous update influencing …

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear

Celcuity beats second quarter loss estimates

Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …

Securitize Corp. (SECZ) completes SPAC merger, raises $197.8M PIPE

Securitize Corp. (SECZ) has completed its SPAC merger with Cantor Equity Partners II, Inc. and Old Securitize, raising approximately $197.8 million through a PIPE investment. The company, now trading on the NYSE under SECZ, reported 163,265,685 common shares outstanding post-merger. Management also identified material …

Atlanticus Holdings Corporation Declares Quarterly Dividend on Series B Cumulative Perpetual Preferred Stock

Atlanticus Holdings Corporation announced a quarterly dividend of $0.476563 per share for its Series B Cumulative Perpetual Preferred shareholders, payable on or about September 15, 2026, to shareholders of record by September 1, 2026. The company focuses on providing inclusive financial services and has …

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

Docusign to Announce Second Quarter Fiscal 2027 Financial Results on September 3, 2026

Docusign (Nasdaq: DOCU) announced it will release its second quarter fiscal 2027 financial results after the U.S. markets close on Thursday, September 3, 2026. The company will host a conference call and live webcast on the same day at 5:00 p.m. Eastern Time to …

Blackstone Secured Lending Fund Extends Key Credit Facilities

Blackstone Secured Lending Fund (BXSL) has amended its senior secured credit agreement with Citibank, N.A., extending key credit facilities. The amendment shifts the maturity dates for certain revolving commitments to 2030 and 2031, while slightly reducing overall aggregate commitments but increasing some revolving and …

Atlanticus Schedules Preferred Dividend Cash Payment Around Sept. 15

Atlanticus Holdings Corporation announced that its Board of Directors approved a quarterly cash dividend of $0.476563 per share for holders of its Series B Cumulative Perpetual Preferred Stock. The dividend is scheduled to be paid on or about September 15, 2026, to shareholders of …

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

IceCure Medical (Nasdaq: ICCM) updates filing for 533,334 warrant-share resales

IceCure Medical Ltd. has filed a post-effective amendment to its Form F-1 to update financial information and maintain the effectiveness of a resale registration. This filing concerns the potential resale of up to 533,334 Ordinary Shares by existing selling shareholders, which are issuable upon …

IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds

IceCure Medical Ltd. has filed a post-effective amendment to register the issuance of up to 324,802 Ordinary Shares upon the exercise of outstanding warrants from a previous rights offering. The exercise includes warrants at $30.00 per share and pre-funded warrants at $0.003 per share, …

Kratos Stock Stumbles Into Q4 Earnings After Red-Hot Run: Can Contracts Offset Margin Fears?

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Strattec CEO and CFO to present at Midwest IDEAS event Aug. 27

Strattec (Nasdaq: STRT) announced that its President & CEO, Jennifer Slater, and CFO, Matthew Pauli, will present and host investor meetings at the Midwest IDEAS Investor Conference on August 27, 2026. The presentation is scheduled for 9:15 a.m. Central Time and a live audio …

UY Scuti Acquisition Corp. Reports Earnings Results for the First Quarter Ended June 30, 2026

Celcuity GAAP EPS of -$1.44 misses by $0.28

* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …

UY Scuti (UYSC) outlines Isdera merger plan, extensions and $25M redemptions

UY Scuti Acquisition Corp. (UYSC) reported unaudited results for the quarter ended June 30, 2026, detailing $35.6 million in its Trust Account after $25.3 million in shareholder redemptions. The company secured $900,000 in sponsor and Isdera affiliate funding for two three-month extensions to complete …

CuriosityStream (NASDAQ: CURI) posts higher Q2 2026 profit on licensing surge

Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12

Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments …

4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss

FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise

A stockholder of 4D Molecular Therapeutics, Inc. (FDMT) has filed to sell 1,635 common shares on NASDAQ, to be issued through the exercise of stock options for cash on August 13, 2026. This filing also discloses previous Rule 10b5-1 plan sales by Scott Bizily …

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics (4DMT) reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for wet AMD and DME, including completed enrollment for two Phase 3 trials for 4D-150 and strong two-year data from its PRISM Phase 2b study. The company …